Cargando…

Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates

BACKGROUND: This study sought to assess the pharmacokinetic and pharmacodynamic relationships of caffeine citrate therapy in preterm neonates who had therapeutic drug monitoring (TDM) in the post-extubation period. METHODS: A retrospective observational study was conducted in preterm neonates who re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tian, Balch, Alfred H., Ward, Robert M., Korgenski, E. Kent, Sherwin, Catherine M. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896039/
https://www.ncbi.nlm.nih.gov/pubmed/27266401
http://dx.doi.org/10.1186/s40360-016-0065-x
_version_ 1782435975275741184
author Yu, Tian
Balch, Alfred H.
Ward, Robert M.
Korgenski, E. Kent
Sherwin, Catherine M. T.
author_facet Yu, Tian
Balch, Alfred H.
Ward, Robert M.
Korgenski, E. Kent
Sherwin, Catherine M. T.
author_sort Yu, Tian
collection PubMed
description BACKGROUND: This study sought to assess the pharmacokinetic and pharmacodynamic relationships of caffeine citrate therapy in preterm neonates who had therapeutic drug monitoring (TDM) in the post-extubation period. METHODS: A retrospective observational study was conducted in preterm neonates who received caffeine citrate therapy for apnea of prematurity and had TDM done in the post-extubation period between January 2006 and October 2011. The relationships between pharmacodynamic effects (heart rate, respiratory rate, episodes of apnea, adverse events) and caffeine serum concentrations were explored. RESULTS: A total of 177 blood samples were obtained from 115 preterm neonates with a median (range) gestational age of 29 (24 – 33) weeks and birth weight of 1230 (607 – 2304) kg. Caffeine citrate therapy was initiated at a median (interquartile range) postnatal age of 1 (1 – 3) day and TDM was performed at a postnatal age of 15 (10 – 24) days. No direct correlations were found between respiratory rate or apneic episodes and caffeine serum concentrations; however, heart rate and caffeine serum concentrations were significantly correlated (p < 0.05). Dosing regimen of 40/5 mg/kg q12h (loading dose/maintenance dose, time interval) led to similar endotracheal re-intubation rate but increased percentage of patients experiencing tachycardia compared to the standard regimen of 20/5 mg/kg q24h (44.7 % vs 10.2 %, p < 0.001). CONCLUSION: Based on this retrospective study, no correlation between episodes of apnea and caffeine serum concentrations was found in neonates who had TDM of caffeine citrate therapy in the post-extubation period, whereas a significant association between tachycardia and concentrations existed. Notwithstanding the absence of severe adverse reactions, TDM should be considered in critically ill neonates with unexplained adverse effects, such as tachycardia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0065-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4896039
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48960392016-06-08 Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates Yu, Tian Balch, Alfred H. Ward, Robert M. Korgenski, E. Kent Sherwin, Catherine M. T. BMC Pharmacol Toxicol Research Article BACKGROUND: This study sought to assess the pharmacokinetic and pharmacodynamic relationships of caffeine citrate therapy in preterm neonates who had therapeutic drug monitoring (TDM) in the post-extubation period. METHODS: A retrospective observational study was conducted in preterm neonates who received caffeine citrate therapy for apnea of prematurity and had TDM done in the post-extubation period between January 2006 and October 2011. The relationships between pharmacodynamic effects (heart rate, respiratory rate, episodes of apnea, adverse events) and caffeine serum concentrations were explored. RESULTS: A total of 177 blood samples were obtained from 115 preterm neonates with a median (range) gestational age of 29 (24 – 33) weeks and birth weight of 1230 (607 – 2304) kg. Caffeine citrate therapy was initiated at a median (interquartile range) postnatal age of 1 (1 – 3) day and TDM was performed at a postnatal age of 15 (10 – 24) days. No direct correlations were found between respiratory rate or apneic episodes and caffeine serum concentrations; however, heart rate and caffeine serum concentrations were significantly correlated (p < 0.05). Dosing regimen of 40/5 mg/kg q12h (loading dose/maintenance dose, time interval) led to similar endotracheal re-intubation rate but increased percentage of patients experiencing tachycardia compared to the standard regimen of 20/5 mg/kg q24h (44.7 % vs 10.2 %, p < 0.001). CONCLUSION: Based on this retrospective study, no correlation between episodes of apnea and caffeine serum concentrations was found in neonates who had TDM of caffeine citrate therapy in the post-extubation period, whereas a significant association between tachycardia and concentrations existed. Notwithstanding the absence of severe adverse reactions, TDM should be considered in critically ill neonates with unexplained adverse effects, such as tachycardia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-016-0065-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-07 /pmc/articles/PMC4896039/ /pubmed/27266401 http://dx.doi.org/10.1186/s40360-016-0065-x Text en © Yu et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yu, Tian
Balch, Alfred H.
Ward, Robert M.
Korgenski, E. Kent
Sherwin, Catherine M. T.
Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title_full Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title_fullStr Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title_full_unstemmed Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title_short Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
title_sort incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896039/
https://www.ncbi.nlm.nih.gov/pubmed/27266401
http://dx.doi.org/10.1186/s40360-016-0065-x
work_keys_str_mv AT yutian incorporatingpharmacodynamicconsiderationsintocaffeinetherapeuticdrugmonitoringinpretermneonates
AT balchalfredh incorporatingpharmacodynamicconsiderationsintocaffeinetherapeuticdrugmonitoringinpretermneonates
AT wardrobertm incorporatingpharmacodynamicconsiderationsintocaffeinetherapeuticdrugmonitoringinpretermneonates
AT korgenskiekent incorporatingpharmacodynamicconsiderationsintocaffeinetherapeuticdrugmonitoringinpretermneonates
AT sherwincatherinemt incorporatingpharmacodynamicconsiderationsintocaffeinetherapeuticdrugmonitoringinpretermneonates